The Drugs Controller General of India has given permission for conducting Phase-1 human clinical trial for an antisera that was developed by injecting inactivated SARS-CoV-2 in horses and can be a potential treatment for Covid-19, ICMR officials said on Tuesday.
The antisera has been developed by the Indian Council of Medical Research in collaboration with a Hyderabad-based bio-pharmaceutical firm.
"With Biological E Limited we have developed an horse 'antisera' and we have just got clearance for conducting clinical trials for that," ICMR Director General Dr Balram Bhargava said at press briefing on Tuesday.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
The antisera is yet to undergo human clinical trials to establish safety and efficacy.
Antisera are blood serum high in antibodies against specific antigens and are injected in humans to help kickstart the immune system to fight specific infections.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
"The ICMR and Biological E Limited, Hyderabad, have developed highly purified antisera (raised in animals) for prophylaxis and treatment of Covid-19," the apex health research body had earlier said in a tweet.
The pre-print version of the study regarding the development of the equine antisera has been posted on the Research Square platform.
"The study provides evidence of the potential of generating highly purified F(ab')2 from equines against SARS-CoV-2 that can demonstrate consistent and high neutralisation activity," the study paper said.
"Further, in-vivo testing for efficacy of this indigenously developed, cost effective product will pave the way to clinical evaluation. Additionally, being a donor independent method, this may prove as an efficient alternative to convalescent plasma for treatment of Covid-19 patients," it said.
Earlier such measures were used for controlling several viral and bacterial infections.
"Although, plasma recovered from patients experiencing Covid-19 could serve similar purpose, the profile of antibodies, their efficacy and concentration keep varying from one patient to another and therefore, make it an unreliable clinical tool for patient management," the ICMR had said in a tweet.
"Standardisation achievable through equine sera based treatment modality thus stands out as yet another remarkable public health initiative supported by ICMR in the time of Covid-19," it said.
As part of the study, 10 healthy horseswere immunised with inactivated SARS-CoV-2 and after 21 days of immunisation, plasma samples were tested.
The results of the plasma samples indicated presence of SARS-CoV-2 specific IgG antibodies as detected in ELISA with neutralising capacity.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
